Navigation Links
Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
Date:10/29/2009

ent with Caldolor. For full prescribing information, including boxed warning, visit www.caldolor.com.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's product portfolio includes Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen poisoning and Kristalose® (lactulose) for Oral Solution, a prescription laxative. The Company also recently launched Caldolor® (ibuprofen) Injection, the first injectable treatment for pain and fever available in the United States. Cumberland is dedicated to providing innovative products which improve quality of care for patients. The Company completed the initial public offering of its common stock in August 2009. For more information on Cumberland Pharmaceuticals, please visit www.cumberlandpharma.com.

About Phebra

Phebra is an Australian based specialty pharmaceutical company that develops and markets critical medicines in Australia, New Zealand, Asia, Canada and parts of Europe. For more information about Phebra please refer to the company website at www.phebra.com.

Important Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that reflect Cumberland's and Phebra's current views with respect to future events, based on what they believe are reasonable assumptions. No assurance can be given, however, that these events will occur. As with any business, all phases of operations are subject to influences outside of the companies' control. Risk factors that could material
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... , June 2, 2015  Only a quarter of ... managing the patients they prescribe them to, according to ... School of Medicine (BUSM) and myCME , ... Daniel Alford, M.D. , director of BUSM,s ... program , said, "This indicates a critical need for ...
(Date:6/2/2015)... -- ErgoNurse, the leader in bedside safety management solutions, and Briggs ... the United States , have formalized a partnership to ... nursing markets. ... Thousands of healthcare professionals in acute ... the ErgoNurse products to stop unnecessarily utilizing their backs for ...
(Date:6/2/2015)... -- CytRx Corporation (NASDAQ: CYTR ), a biopharmaceutical research ... it has reached an agreement to settle the stockholder ... Court of Chancery, which names as defendants a ... officers, and names the Company as a nominal defendant. ... Corp. Stockholder Derivative Litigation , C.A. No. 9864-VCL, relates ...
Breaking Medicine Technology:Survey Results Show Few Doctors Are Very Confident Managing Patients on Opioids 2ErgoNurse and Briggs Healthcare Positioned to Completely Eliminate the Unnecessary Cost of Healthcare-Related Back Injuries 2CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware 2CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware 3CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware 4
... Vaginal Supplement Studied in Largest-Ever IVF Trial,in ... /PRNewswire/ -- Results of,four studies evaluating Ferring ... development for luteal phase,support (supplementation to provide ... pregnancy) in assisted reproductive,technologies (ART) were presented ...
... April 18, 2007,/PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today ... a functional,biomarker for its novel histone deacetylase ... with its,Bruton's tyrosine kinase (BTK) inhibitor compounds. ... for Cancer Research (AACR),2007 Annual Meeting being ...
Cached Medicine Technology:Ferring Reports on ENDOMETRIN Presentations at Pacific Coast,Reproductive Society Annual Meeting 2Ferring Reports on ENDOMETRIN Presentations at Pacific Coast,Reproductive Society Annual Meeting 3Ferring Reports on ENDOMETRIN Presentations at Pacific Coast,Reproductive Society Annual Meeting 4Ferring Reports on ENDOMETRIN Presentations at Pacific Coast,Reproductive Society Annual Meeting 5Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC,Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with,Bruton's Tyrosine Kinase Inhibitors 2Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC,Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with,Bruton's Tyrosine Kinase Inhibitors 3Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC,Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with,Bruton's Tyrosine Kinase Inhibitors 4Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC,Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with,Bruton's Tyrosine Kinase Inhibitors 5
(Date:6/2/2015)... 02, 2015 On Wednesday, May 27, 2015, ... to a top speed of 207.9 mph. In the ... to break the 200 mph mark. Jay Leno was ... upcoming episode of Jay Leno’s Garage, which will air on ... the 8.5 mile high speed oval at the Continental Tire ...
(Date:6/2/2015)... UCLA Health and Exer have completed negotiations ... expand urgent care services in Los Angeles County. ... of California Board of Regents and the Exer Board ... to purchase a minority share of four existing Exer ... and Northridge and creates opportunity to grow and develop ...
(Date:6/2/2015)... Prussia, PA (PRWEB) June 02, 2015 ... Outsourcing solutions for health plans in the Medicare Advantage, ... participation as a sponsor and exhibitor at AHIP’s Institute ... America’s Health Insurance Plans. The conference will be held ... exhibition booth, #1303, will offer opportunities for attendees to ...
(Date:6/2/2015)... June 02, 2015 On October 1, ... efforts for another delay. , On Monday, June ... Subcommittee for the House Ways and Means Committee, and ... Centers for Medicare and Medicaid Services, urging the administration ... CMS rolls out ICD-10. ICD-10 is the newest coding ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 IMPAK ... sorbent systems, has announced the availability of “child-resistant” ... of poisons by children, especially curious toddlers. The ... standards and tested to CFR 1700.20 protocols. The ... Cullen. , Looks Like Candy, “With the proliferation ...
Breaking Medicine News(10 mins):Health News:774 HP Hennessey Mustang Tested to 207.9 mph 2Health News:UCLA Health Partners With Exer - More Than Urgent Care 2Health News:TMG Health to Sponsor and Exhibit at AHIP’s Institute 2015 2Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 2Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 3Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 4Health News:IMPAK Introduces Child Resistant Zip Pouches & Bags 2
... MINNEAPOLIS, Dec. 18 MinuteClinic medical clinics in select ... now offering H1N1 vaccinations on demand seven days a ... be obtained at MinuteClinic locations in Maryland in Baltimore ... in North Carolina in Charlotte, Greensboro, Winston-Salem and Raleigh-Durham; ...
... people who have received solid organ transplants and veterinarians should ... That,s just one of the key pieces of advice from ... in the American Journal of Transplantation . ... by members of the American Society of Transplantation,s Infectious Diseases ...
... understanding of TAK1 could lead to new treatments for ... News) -- A protein switch called TAK1 helps prevent ... a team of scientists from the United States and ... improve understanding about the development of liver disease and ...
... , ... Operations to offer enhanced capabilities , ... Milford, NH and Marlboro, MA (PRWEB) December 18, 2009 -- Degree ... electronics and telecommunications industries, announced today that it has sold its IQS Testing business ...
... ... connect with clients and prospective clients, , ... Glendale, CA (Lexis Nexis) December 18, 2009 -- Milton & DeKruif, a Glendale ... it has kicked off an aggressive new client development campaign in order to raise its ...
... ... and create applications on all of their software and hardware platforms -- both new ... ... Systems announced a detailed 2010 product roadmap for NXTware Remote, its Eclipse-based cross-platform ...
Cached Medicine News:Health News:CVS MinuteClinic Now Providing H1N1 Vaccinations On Demand at all Locations in Maryland, North Carolina and Tennessee 2Health News:CVS MinuteClinic Now Providing H1N1 Vaccinations On Demand at all Locations in Maryland, North Carolina and Tennessee 3Health News:Transplant guide highlights daily infection risks from factors like pets and food 2Health News:Transplant guide highlights daily infection risks from factors like pets and food 3Health News:IQS Testing Purchased by The Compliance Management Group 2Health News:IQS Testing Purchased by The Compliance Management Group 3Health News:Milton & DeKruif Launches New Client Development Campaign 2Health News:eCube Announces 2010 NXTware Remote Product Roadmap 2Health News:eCube Announces 2010 NXTware Remote Product Roadmap 3Health News:eCube Announces 2010 NXTware Remote Product Roadmap 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: